NASDAQ NMS - GLOBAL MARKET · DNTH
0.00% · $0.0000 · Vol Not reported
Pre-market · updated 04:08:39 ET
Dianthus Therapeutics Inc

Dianthus Therapeutics Inc

Biotechnology
$82.43
Card
Relationship Map

Follow $DNTH

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $DNTH by email

Veridion Score

BETAHIGH CONF · 6 of 6 factors measuredMethodology
DNTH
Dianthus Therapeutics Inc
Thu Oct 8 · last completed session · Pre-market · regular session opens 9:30 ET
Lower range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

43/ 100
Veridion Score
Lower range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Thu Oct 8 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is DNTH moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading DNTH catalysts
About Dianthus Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2023
Employees
92
Country
US

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$82.43
Last session
Day high
$82.43
Last session
Day low
$82.43
Last session
Previous close
$82.43
52W high
$115.96
-28.92% from high
52W low
$32.92
60% of range
Market cap
$4.6B
EPS
$-4.1496
Beta
0.70
Shares out
55.9M
Avg volume
829.5K
VWAP
$82.43
Last session
Price history computed in-house
1W
-6.55%
1M
-22.99%
3M
-15.54%
1Y
+137.21%
YTD
+100.02%
SMA 50 $103.23 · below
SMA 200 $82.01 · above
52W position 60%

DNTH overview

Veridion Score
43
Registered · 2026-10-08
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around DNTH.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading DNTH Form 4 filings
Public disclosures

Congress activity in DNTH

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

DNTH contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for DNTH in this window.
Lobbying spend

DNTH lobbying filings, year to date.

Registered lobbying filings matched to Dianthus Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for DNTH in this window.
Loading news for DNTH
Analyst ratings
Sovereign unlock shows live analyst consensus for DNTH.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.